|
Abnova Corporation CEO Dr. Wilber Huang is invited to speak at がん研究ツール最前線 2019 held in Tokyo, Japan. Dr. Huang’s speech highlights the circulating tumor cell (CTC) in the new era of precision medicine.
Invited Speaker: Wilber Huang, MD Topic: CTC in the New Era of Precision Medicine Date: October 28th, 2019 Venue: TKP ガーデンシティ品川 |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)